[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [TECHNOLOGY]

3 clusters · 7 sources · 9 days · First seen · Last updated

Wandercraft medical exoskeleton market expansion

Overview

French company Wandercraft expanded its presence in the medical exoskeleton market through regulatory milestones and strategic acquisition.

In late September 2026, the U.S. Food and Drug Administration (FDA) cleared the commercial launch of Eve, a self-balancing robotic exoskeleton designed for adults with spinal cord injuries. The device allows users to stand and walk without crutches or walkers, utilizing twelve motors and integrated sensors to maintain stability. The technology incorporates advanced robotics and artificial intelligence to maintain stability while allowing for hands-free movement, which enables users to perform daily tasks, such as handling objects or preparing food, independently.

Following this launch, Wandercraft completed the acquisition of Ekso Bionics. This merger combined Wandercraft’s robotics expertise with Ekso Bionics’ established U.S. clinical infrastructure, creating the world’s largest manufacturer of medical exoskeletons. The unified company maintains a portfolio of four specialized systems for clinical rehabilitation and individual mobility, serving over 700 research and rehabilitation centers globally.

Entities

Wandercraft · Eve · Ekso Bionics · ChronoScale Holdings · FDA

Timeline

  1. [TECHNOLOGY] 2 sources
    Wandercraft exoskeleton receives US approval for spinal cord injury mobility

    Wandercraft’s Eve robotic exoskeleton has received US approval, helping people with spinal cord injuries walk and move hands-free using AI and advanced robotics.

  2. [BUSINESS] 2 sources
    Wandercraft acquires Ekso Bionics to lead medical exoskeleton market

    Wandercraft has acquired Ekso Bionics from ChronoScale Holdings, creating the world’s largest medical exoskeleton company to serve over 700 rehabilitation centers globally.

  3. [TECHNOLOGY] 3 sources
    Wandercraft's Eve exoskeleton receives FDA clearance for U.S. launch

    The FDA has cleared Wandercraft’s Eve, a self-balancing personal exoskeleton, for commercial use in the U.S. to assist adults with spinal cord injuries in standing and walking.

Sources

ad-hoc-news.de · enigmaplus.cz · hitconsultant.net · mensgear.net · olhardigital.uol.com.br · rehabpub.com · zivot.pluska.sk

This summary has been updated 1 time: see revision history